Replimune Group, Inc. (REPL:NASDAQ) Investor Relations Material

Overview

Biotechnology company Replimune Group, Inc. is utilizing its proprietary Immunotherapy platform to advance oncolytic immuno-gene therapies for the treatment of cancer. The company's lead product candidate, RP1, is in Phase I/II clinical trials for various solid tumors, and Phase II clinical trials for cutaneous squamous cell carcinoma. Replimune is also in the process of developing RP2, which is undergoing Phase I clinical trials to create an anti-CTLA-4 antibody-like protein that blocks the immune response inhibition of CTLA-4. Additionally, RP3 is in Phase I clinical trials to express immune-activating proteins and stimulate T cells. Woburn, Massachusetts has served as the company's headquarters since its founding in 2015.

Annual Reports

Frequently Asked Questions

What is Replimune Group, Inc.'s ticker?

Replimune Group, Inc.'s ticker is REPL

What exchange is Replimune Group, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Replimune Group, Inc.'s headquarters?

They are based in Woburn, Massachusetts

How many employees does Replimune Group, Inc. have?

There are 51-200 employees working at Replimune Group, Inc.

What is Replimune Group, Inc.'s website?

It is https://replimune.com/

What type of sector is Replimune Group, Inc.?

Replimune Group, Inc. is in the Healthcare sector

What type of industry is Replimune Group, Inc.?

Replimune Group, Inc. is in the Biotechnology industry

Who are Replimune Group, Inc.'s peers and competitors?

The following five companies are Replimune Group, Inc.'s industry peers:

- Fennec Pharmaceuticals

- Onconova Therapeutics

- Akero Therapeutics, Inc.

- BioCardia, Inc.

- Codexis